Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

This study tests a combination of immunotherapy drugs (serplulimab and nimotuzumab) added to standard pre-surgery chemoradiation for patients with locally advanced esophageal squamous cell cancer (a cancer of the food pipe) that can potentially be removed with surgery. The hope is that adding these immune-boosting drugs will improve how much the cancer shrinks before surgery and lead to better long-term outcomes. **You may be eligible if...** - You are between 18 and 75 years old with confirmed esophageal squamous cell cancer at a locally advanced stage - You have not received any prior treatment for this cancer - Your cancer is expected to be completely removable by surgery - You have no evidence of spread to distant organs - Your organ function (blood counts, liver, kidneys, heart, lungs) meets the required minimum levels **You may NOT be eligible if...** - You have received EGFR-targeted drugs in the past 6 months - You have serious heart failure, uncontrolled high blood pressure, renal failure, severe diabetes, or mental disorders - You have brain metastases with symptoms - You have had another cancer in the past 5 years (with some exceptions) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.